So far, no causal treatment is available for HPMRS. A mouse model that mirroring the human phenotype has been engineered by Crispr-Cas technology and is available for compound screening.
Hyperphosphatasia with mental retardation syndrome
Malignant infantile osteopetrosis
Diffuse idiopathic skeletal hyperostosis
Normophosphatemic familial tumoral calcinosis
Gerodermia osteodysplastica
Bing–Neel syndrome
Autosomal dominant hypophosphatemic rickets
MDP syndrome